We would love to hear your thoughts about our site and services, please take our survey here.
We have no news and potential rumours always seem to push up the share and as you say soon as the news lands on most occasions, unless its news out of the blue we expect a fail back to the support level. MM try to do the tree shaking and hover up some cheap stock. Never set a 10% limit on a stock you believe in is my philosophy. I here for long term hold as I believe in CF. We have a great captain at the helm steering us in the right direction.
This still has great potential and what we have in the pipe line for 2021. Slow burner but steady grower.
Concepts
provision of lateral flow test kits
diagnostic supplies
part of the uk covid-19 testing strategy
antibody testing
use
support of pillar
covid-19
I think sometimes people loose sight and get caught up in the speculation .
Lots of validation of what we are doing and when in Junes presentation .
By November increase production facilities in place. 120m tests per month in U.K. production by Abingdon Health.
Also talking to South East Asia areas . This could dwarf anything in the U.K. in the 100m-200m small offerings by the gov.
Clinical validation Q4 2020 for CE marking.
Not long to wait for all this to drop in soon.
194 will then be the distant past. I am long term hold and see this only becoming another multi bagger.
If I am not mistaken Boris today almost quoted Dr Alastair Smith statement from Yorkshire Post from 20th Sept 2020.
h**ps://www.yorkshirepost.co.uk/business/consumer/avacta-set-momentous-milestones-it-prepares-launch-covid-19-test-2985152
Dr Alastair Smith, chief executive of Avacta Group, said there is also overseas manufacturing capacity.
He stressed that it is vital to carry out the proper clinical procedures to ensure the test is effective.
"It is really important we do this properly because it takes a lot of risk out of the process," he added.
"If we don't, if we rush it and don't do it properly, it just pushes the risk down the line into the clinical validation."
RNS is all positive. Something in the wings about to drop. Surprise how it rises before RNS . Finncap not the best to be involved with . Expect rollacoaster share price with them on board to suck up shares cheap.They want our shares so hold on is my forecast as this company is going places Q1 2021.
The game changer is the POC LFD quick test and validation. No labs or special machines required . Open to everyone and will allow lots of venues and business to re-open.
The spit on the stick will become the norm and this will be huge for sales. It also opens the way for future diagnosis for flu and other viruses. The potential is mind blowing.
Interesting
https://www.guilfordco.wales/consortium-completes-successful-coronavirus-study/
Down at 50 big drop. Cost per test £3-£4 ( When in large volumes so small volumes will be a lot more) but you need a machine so not a stand alone test. O.k. if you can afford a test machine at your work or venue.
I BOD did carry out an investigation into Boatman.
"Having possibly identified the investigator behind the short seller Boatman Capital Research, investigation giant Kroll has reaffirmed its status as a hunter of anonymous raiders who bet on a company's stock market value falling before publishing a negative report.15 Jan 2020"
RR have some good fundamentals but they have all there eggs in one basket which is aviation at near rock bottom and look to get worse. Until flights start to take to the air and the industry need to look to place any orders they will be behind the curve. Fights will only resume when we have full passenger testing at airports as the vaccine is Q2 2021. The tests will come
hopefully November 2020 with a 10 min spit on a stick test " yes you can fly". Ingress passengers will also be tested to stop the spread. This should then make people more confident to travel.
They have laid off a lot of staff and we are not at the end of October when the government furlough scheme ends.
Great British company which might be bought at these low SP and evaluation.
Just seen Gabriel on Bloomberg. Emphasis on treatment rather than vaccines for covin. The inhaler is 1 year ahead of trial and backed up RNS . November list for Stem.
We now know the road map and dates for STemPRintER with the ex-div and cut-off date being the 30th Oct with a listing 2 months later.
Positive news and a rally on the SP.if your not in on the 30th Oct . HOLD existing stocks with big top before the cut off date. This news is on the mark with dates and time scales so no surprises to cause a investors reaction. Do not take your eye off the .ball on other activities which could be some good news soon. Just look at the previous road map and dates pipeline.
2020 not 2021
StemPrintER date is definitely a typo as Gabriel in this last talks spoke about Oct/Nov for Stem spin off to be completed once the tax situation is sorted. The cut off date will be before this completion to get your 1:1 shares in Accustem Biosciences.
Latest update from yesterday on SP. Interesting update.
Go to 40 mins.
https://www.youtube.com/watch?v=aaguza4wO9I
Talk on (SKIN) Integumen Regulatory News site about this RNS on 13th July.
Partners with Avacta for novel SARS-CoV-2 sensors
https://www.lse.co.uk/rns/SKIN/partners-with-avacta-for-novel-sars-cov-2-sensors-ozf2c0m9pd4w9z2.html
"Once initial testing of the Affimer reagents is completed over the next few weeks, validation of the sensors will be carried out using SARS-COV-2 virus samples in a containment level 3 laboratory at the University of Aberdeen. Upon successful completion of this evaluation, Integumen and Avacta will enter into a supply agreement to allow Integumen to manufacture and commercialise the waste water detection sensors globally by retrofitting into Microtox systems."
We might be one or two weeks away. I like the last statement "This collaboration has the potential to deliver a product that will play a crucial role in the early detection of COVID-19 hotspots around the world."
Link is working fine in the RNS . Reassuring that we have so many patients and all landing also with future patients pending.
Another opportunity day. Top up my golden pile in this company . Had a limit set today and it triggered so topped up on the dip. £1.45..
I believe in this company and its pipeline businesses. Stem is the icing on the cake which is a bonus.